{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T22:51:44Z","timestamp":1788821504301,"version":"build-2803163510"},"reference-count":65,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,11,26]],"date-time":"2019-11-26T00:00:00Z","timestamp":1574726400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["K08 DK118120"],"award-info":[{"award-number":["K08 DK118120"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["kireports.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney International Reports"],"published-print":{"date-parts":[[2020,2]]},"DOI":"10.1016\/j.ekir.2019.11.015","type":"journal-article","created":{"date-parts":[[2019,12,6]],"date-time":"2019-12-06T21:33:13Z","timestamp":1575667993000},"page":"149-158","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":69,"title":["Systematic Review of the Safety of Immune Checkpoint Inhibitors Among Kidney Transplant Patients"],"prefix":"10.1016","volume":"5","author":[{"given":"Sandhya","family":"Manohar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charat","family":"Thongprayoon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wisit","family":"Cheungpasitporn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svetomir N.","family":"Markovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandra M.","family":"Herrmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ekir.2019.11.015_bib1","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1056\/NEJM199912023412303","article-title":"Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant","volume":"341","author":"Wolfe","year":"1999","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2019.11.015_bib2","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1038\/ki.1996.307","article-title":"A\u00a0study of the quality of life and cost-utility of renal transplantation","volume":"50","author":"Laupacis","year":"1996","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2019.11.015_bib3","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1093\/ndt\/16.8.1545","article-title":"Causes of death after renal transplantation","volume":"16","author":"Briggs","year":"2001","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.ekir.2019.11.015_bib4","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1097\/TP.0b013e3181caeead","article-title":"Reduction in cardiovascular death after kidney transplantation","volume":"89","author":"Pilmore","year":"2010","journal-title":"Transplantation"},{"key":"10.1016\/j.ekir.2019.11.015_bib5","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1001\/jama.2011.1592","article-title":"Spectrum of cancer risk among US solid organ transplant recipients","volume":"306","author":"Engels","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.ekir.2019.11.015_bib6","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1001\/jama.296.23.2823","article-title":"Cancer incidence before and after kidney transplantation","volume":"296","author":"Vajdic","year":"2006","journal-title":"JAMA"},{"issue":"Suppl 15","key":"10.1016\/j.ekir.2019.11.015_bib7","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1681\/ASN.V11suppl_1s1","article-title":"Recommendations for the outpatient surveillance of renal transplant recipients. American Society of Transplantation","volume":"11","author":"Kasiske","year":"2000","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.ekir.2019.11.015_bib8","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1097\/00007890-199601270-00019","article-title":"Malignant melanoma in organ allograft recipients","volume":"61","author":"Penn","year":"1996","journal-title":"Transplantation"},{"key":"10.1016\/j.ekir.2019.11.015_bib9","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.ekir.2019.11.015_bib10","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1053\/j.gastro.2017.01.063","article-title":"Tapering of immunosuppression and sustained treatment with nivolumab in a liver transplant recipient","volume":"152","author":"De Toni","year":"2017","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ekir.2019.11.015_bib11","first-page":"211","article-title":"Administration of ipilimumab to a liver transplant recipient with unresectable metastatic melanoma","volume":"38","author":"Ranganath","year":"2015","journal-title":"J\u00a0Immunother"},{"key":"10.1016\/j.ekir.2019.11.015_bib12","doi-asserted-by":"crossref","first-page":"e26682","DOI":"10.1002\/pbc.26682","article-title":"Fatal orthotopic liver transplant organ rejection induced by a checkpoint inhibitor in two patients with refractory, metastatic hepatocellular carcinoma","volume":"64","author":"Friend","year":"2017","journal-title":"Pediatr Blood Cancer"},{"key":"10.1016\/j.ekir.2019.11.015_bib13","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s40425-015-0066-0","article-title":"Safety and efficacy of ipilimumab to treat advanced melanoma in the setting of liver transplantation","volume":"3","author":"Morales","year":"2015","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.ekir.2019.11.015_bib14","doi-asserted-by":"crossref","first-page":"361","DOI":"10.7326\/L17-0187","article-title":"Immune checkpoint inhibitor therapy in a liver transplant recipient with melanoma","volume":"167","author":"Schvartsman","year":"2017","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ekir.2019.11.015_bib15","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1093\/annonc\/mdx548","article-title":"Safety of an anti-PD-1 immune checkpoint inhibitor in a liver transplant recipient","volume":"29","author":"Biondani","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ekir.2019.11.015_bib16","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1097\/CMR.0000000000000410","article-title":"Immune checkpoint inhibitor therapy in a liver transplant recipient with a rare subtype of melanoma: a case report and literature review","volume":"28","author":"Kuo","year":"2018","journal-title":"Melanoma Res"},{"key":"10.1016\/j.ekir.2019.11.015_bib17","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s00262-016-1918-2","article-title":"Cardiac allograft rejection as a complication of PD-1 checkpoint blockade for cancer immunotherapy: a case report","volume":"66","author":"Owonikoko","year":"2017","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.ekir.2019.11.015_bib18","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1093\/annonc\/mdw293","article-title":"Tolerability of immune checkpoint inhibition cancer therapy in a cardiac transplant patient","volume":"27","author":"Gastman","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ekir.2019.11.015_bib19","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/bmt.2017.44","article-title":"Nivolumab before and after allogeneic hematopoietic cell transplantation","volume":"52","author":"Covut","year":"2017","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.ekir.2019.11.015_bib20","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/bmt.2015.266","article-title":"Nivolumab in a patient with refractory Hodgkin\u2019s lymphoma after allogeneic stem cell transplantation","volume":"51","author":"Angenendt","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.ekir.2019.11.015_bib21","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1111\/ajt.15071","article-title":"Ipilimumab for the treatment of advanced melanoma in six kidney transplant patients","volume":"18","author":"Zehou","year":"2018","journal-title":"Am J Transplant"},{"key":"10.1016\/j.ekir.2019.11.015_bib22","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1111\/tri.12834","article-title":"Mixed acute kidney allograft rejection after an antiprogrammed cell death protein 1 antibody treatment for lung epidermoid carcinoma","volume":"29","author":"Tamain","year":"2016","journal-title":"Transplant Int"},{"key":"10.1016\/j.ekir.2019.11.015_bib23","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.1016\/j.transproceed.2016.07.019","article-title":"Renal allograft failure after ipilimumab therapy for metastatic melanoma: a case report and review of the literature","volume":"48","author":"Jose","year":"2016","journal-title":"Transplant Proc"},{"key":"10.1016\/j.ekir.2019.11.015_bib24","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.ejca.2018.12.027","article-title":"CMV disease and colitis in a kidney transplanted patient under pembrolizumab","volume":"109","author":"Gueguen","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ekir.2019.11.015_bib25","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.ejca.2018.09.017","article-title":"Anti-PD-1\/PD-L1 immunotherapy in patients with solid organ transplant, HIV or hepatitis B\/C infection","volume":"104","author":"Tio","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ekir.2019.11.015_bib26","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ejca.2016.07.026","article-title":"Checkpoint inhibitors in chronic kidney failure and an organ transplant recipient","volume":"67","author":"Herz","year":"2016","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ekir.2019.11.015_bib27","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1186\/s40425-016-0171-8","article-title":"Antitumor activity of nivolumab on hemodialysis after renal allograft rejection","volume":"4","author":"Ong","year":"2016","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.ekir.2019.11.015_bib28","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.1210\/jc.2018-01430","article-title":"PD-1 inhibitor immune-related adverse events in patients with preexisting endocrine autoimmunity","volume":"103","author":"Akturk","year":"2018","journal-title":"J\u00a0Clin Endocrinol Metab"},{"key":"10.1016\/j.ekir.2019.11.015_bib29","doi-asserted-by":"crossref","first-page":"e69","DOI":"10.1200\/JCO.2013.49.2314","article-title":"Successful administration of ipilimumab to two kidney transplantation patients with metastatic melanoma","volume":"32","author":"Lipson","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ekir.2019.11.015_bib30","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1200\/JOP.2017.027326","article-title":"Complete tumor response to pembrolizumab and allograft preservation in renal allograft recipient on immunosuppressive therapy","volume":"14","author":"Sadaat","year":"2018","journal-title":"J\u00a0Oncol Pract"},{"key":"10.1016\/j.ekir.2019.11.015_bib31","first-page":"341","article-title":"Safe administration of an anti-PD-1 antibody to kidney-transplant patients: 2 clinical cases and review of the literature","volume":"40","author":"Winkler","year":"2017","journal-title":"J\u00a0Immunother"},{"key":"10.1016\/j.ekir.2019.11.015_bib32","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s13256-017-1229-z","article-title":"Pembrolizumab for metastatic melanoma in a renal allograft recipient with subsequent graft rejection and treatment response failure: a case report","volume":"11","author":"Kwatra","year":"2017","journal-title":"J\u00a0Med Case Rep"},{"key":"10.1016\/j.ekir.2019.11.015_bib33","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.ejca.2018.03.019","article-title":"Checkpoint blockade after kidney transplantation","volume":"96","author":"Lesouhaitier","year":"2018","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ekir.2019.11.015_bib34","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1093\/annonc\/mdw130","article-title":"Acute renal allograft rejection after immune checkpoint inhibitor therapy for metastatic melanoma","volume":"27","author":"Spain","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ekir.2019.11.015_bib35","doi-asserted-by":"crossref","first-page":"E52","DOI":"10.1097\/TP.0000000000002502","article-title":"Preserved renal allograft function and successful treatment of metastatic Merkel cell cancer post nivolumab therapy","volume":"103","author":"Singh","year":"2019","journal-title":"Transplantation"},{"key":"10.1016\/j.ekir.2019.11.015_bib36","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s12882-018-1003-5","article-title":"PD 1 checkpoint inhibition in solid organ transplants: 2 sides of a coin - Case report","volume":"19","author":"Goldman","year":"2018","journal-title":"BMC Nephrol"},{"key":"10.1016\/j.ekir.2019.11.015_bib37","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1111\/ajt.13786","article-title":"Use of the PD-1 pathway inhibitor nivolumab in a renal transplant patient with malignancy","volume":"16","author":"Boils","year":"2016","journal-title":"Am J Transplant"},{"key":"10.1016\/j.ekir.2019.11.015_bib38","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1111\/ajt.13711","article-title":"Checkpoint inhibitors in kidney transplant recipients and the potential risk of rejection","volume":"16","author":"Alhamad","year":"2016","journal-title":"Am J Transplant"},{"key":"10.1016\/j.ekir.2019.11.015_bib39","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMc1509268","article-title":"Tumor regression and allograft rejection after administration of anti-PD-1","volume":"374","author":"Lipson","year":"2016","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2019.11.015_bib40","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1093\/annonc\/mdx409","article-title":"Tumor regression and preservation of graft function after combination with anti-PD-1 immunotherapy without immunosuppressant titration","volume":"28","author":"Wu","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ekir.2019.11.015_bib41","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1056\/NEJMc1614298","article-title":"Preserved renal-allograft function and the PD-1 pathway inhibitor nivolumab: To the editor","volume":"376","author":"Barnett","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ekir.2019.11.015_bib42","first-page":"405","article-title":"Severe allograft rejection and autoimmune hemolytic anemia after anti-PD1 therapy in a kidney transplanted patient","volume":"30","author":"Deltombe","year":"2017","journal-title":"Transplant Int"},{"key":"10.1016\/j.ekir.2019.11.015_bib43","first-page":"13","article-title":"Immune checkpoint inhibitors in kidney transplant recipients","volume":"31","author":"Coche","year":"2018","journal-title":"Transplant Int"},{"key":"10.1016\/j.ekir.2019.11.015_bib44","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/j.transproceed.2017.06.007","article-title":"Donor-derived metastatic melanoma and checkpoint inhibition","volume":"49","author":"Boyle","year":"2017","journal-title":"Transplant Proc"},{"key":"10.1016\/j.ekir.2019.11.015_bib45","first-page":"277","article-title":"Immune checkpoint inhibitors in organ transplant patients","volume":"40","author":"Kittai","year":"2017","journal-title":"J\u00a0Immunother"},{"key":"10.1016\/j.ekir.2019.11.015_bib46","first-page":"18","article-title":"The use of checkpoint-inhibitors in metastatic melanoma in a combined heart and kidney transplant recipient. A case report","volume":"31","author":"Soellradl","year":"2018","journal-title":"Transplant Int"},{"key":"10.1016\/j.ekir.2019.11.015_bib47","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.jdcr.2017.06.005","article-title":"Complete pathologic response of metastatic cutaneous squamous cell carcinoma and allograft rejection after treatment with combination immune checkpoint blockade","volume":"3","author":"Miller","year":"2017","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.ekir.2019.11.015_bib48","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1146\/annurev.iy.07.040189.002305","article-title":"Clonal expansion versus functional clonal inactivation: a costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy","volume":"7","author":"Mueller","year":"1989","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.ekir.2019.11.015_bib49","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1111\/j.1600-6143.2012.04224.x","article-title":"Role of the PD-1 pathway in the immune response","volume":"12","author":"Riella","year":"2012","journal-title":"Am J Transplant"},{"key":"10.1016\/j.ekir.2019.11.015_bib50","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1111\/j.1365-2141.2005.05627.x","article-title":"Co-stimulatory pathways in lymphocyte regulation: the immunoglobulin superfamily","volume":"130","author":"Peggs","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ekir.2019.11.015_bib51","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.clim.2005.01.005","article-title":"PD-L1 is expressed by human renal tubular epithelial cells and suppresses T cell cytokine synthesis","volume":"115","author":"Ding","year":"2005","journal-title":"Clin Immunol"},{"key":"10.1016\/j.ekir.2019.11.015_bib52","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/ki.2010.97","article-title":"Renal tubular PD-L1 (CD274) suppresses alloreactive human T-cell responses","volume":"78","author":"Starke","year":"2010","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2019.11.015_bib53","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.mayocp.2012.04.018","article-title":"Melanoma in immunosuppressed patients","volume":"87","author":"Kubica","year":"2012","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.ekir.2019.11.015_bib54","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1097\/CCO.0000000000000505","article-title":"Immune checkpoint blockade for organ transplant patients with advanced cancer: how far can we go?","volume":"31","author":"De Bruyn","year":"2019","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.ekir.2019.11.015_bib55","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s40425-019-0585-1","article-title":"Checkpoint inhibitor therapy for cancer in solid organ transplantation recipients: an institutional experience and a systematic review of the literature","volume":"7","author":"Abdel-Wahab","year":"2019","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.ekir.2019.11.015_bib56","doi-asserted-by":"crossref","unstructured":"Venkatachalam K, Malone AF, Heady B, et\u00a0al. Poor outcomes with the use of checkpoint inhibitors in kidney transplant recipients [e-pub ahead of print]. Transplantation. https:\/\/doi.org\/10.1097\/TP.0000000000002914. Accessed November 2, 2019.","DOI":"10.1097\/TP.0000000000002914"},{"key":"10.1016\/j.ekir.2019.11.015_bib57","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/j.1365-2133.2005.07087.x","article-title":"Reduction of immunosuppression for transplant-associated skin cancer: expert consensus survey","volume":"154","author":"Otley","year":"2006","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.ekir.2019.11.015_bib58","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/17401","article-title":"Cyclosporine induces cancer progression by a cell-autonomous mechanism","volume":"397","author":"Hojo","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.ekir.2019.11.015_bib59","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1097\/01.TP.0000081399.75231.3B","article-title":"Tacrolimus enhances transforming growth factor-beta1 expression and promotes tumor progression","volume":"76","author":"Maluccio","year":"2003","journal-title":"Transplantation"},{"key":"10.1016\/j.ekir.2019.11.015_bib60","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1046\/j.1600-6143.2003.00325.x","article-title":"Lymphomas after solid organ transplantation: a collaborative transplant study report","volume":"4","author":"Opelz","year":"2004","journal-title":"Am J Transplant"},{"key":"10.1016\/j.ekir.2019.11.015_bib61","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1016\/S0140-6736(97)08496-1","article-title":"Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens","volume":"351","author":"Dantal","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.ekir.2019.11.015_bib62","doi-asserted-by":"crossref","first-page":"23665","DOI":"10.1074\/jbc.M804047200","article-title":"Mutagenic and cytotoxic properties of 6-thioguanine, S6-methylthioguanine, and guanine-S6-sulfonic acid","volume":"283","author":"Yuan","year":"2008","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.ekir.2019.11.015_bib63","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1097\/00007890-200205270-00008","article-title":"Rapamycin blocks tumor progression: unlinking immunosuppression from antitumor efficacy","volume":"73","author":"Luan","year":"2002","journal-title":"Transplantation"},{"key":"10.1016\/j.ekir.2019.11.015_bib64","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1046\/j.1523-1755.2003.00805.x","article-title":"Rapamycin is an effective inhibitor of human renal cancer metastasis","volume":"63","author":"Luan","year":"2003","journal-title":"Kidney Int"},{"key":"10.1016\/j.ekir.2019.11.015_bib65","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1097\/01.TP.0000184006.43152.8D","article-title":"Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies","volume":"80","author":"Kauffman","year":"2005","journal-title":"Transplantation"}],"container-title":["Kidney International Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024919315566?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468024919315566?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T03:26:09Z","timestamp":1762831569000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468024919315566"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":65,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["S2468024919315566"],"URL":"https:\/\/doi.org\/10.1016\/j.ekir.2019.11.015","relation":{},"ISSN":["2468-0249"],"issn-type":[{"value":"2468-0249","type":"print"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systematic Review of the Safety of Immune Checkpoint Inhibitors Among Kidney Transplant Patients","name":"articletitle","label":"Article Title"},{"value":"Kidney International Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ekir.2019.11.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 International Society of Nephrology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}